MammaPrint, a 70-gene signature test, might help healthcare providers and patients determine whether they will derive a benefit from chemotherapy, or if they could safely choose to not receive chemotherapy for early-stage breast cancer. These results need to be validated, and compared to other tests in order to confirm findings and determine true clinical utility … Continue reading "MammaPrint Might Help Identify Breast Cancer Patients Who Could Safely Opt Out of Chemo"
The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is referred to as human epidermal growth factor receptor-2 (HER2)-positive. This means that the breast cancer cells have too many HER2 proteins on … Continue reading "Neratinib Improves Cancer-Free Survival in Early Breast Cancer"
Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment. However, quality of life issues, bone density concerns, and a patient’s risk of a recurrence should be taken into consideration to determine the optimal length of … Continue reading "Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer"
Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently published in the Journal of Clinical Oncology. The majority of breast cancers, referred to as hormone-positive breast cancers, … Continue reading "Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen"
Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference (EBCC-10) in the Netherlands. Chemotherapy following surgery is a standard treatment option for premenopausal women diagnosed with … Continue reading "Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival"
The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, … Continue reading "ASCO Publishes Breast Cancer Survivorship Guidelines"